Abstract
Objectives The last five years have seen substantial changes in England’s social and economic landscape as a result of Brexit, the Covid-19 pandemic, and cost-of-living crisis. We aimed to examine changes in cross-border and illicit tobacco purchasing, and associations with quitting activity, over this period.
Design Nationally-representative monthly cross-sectional survey.
Setting England, 2019-2022.
Participants 11,232 adult (≥18y) past-year smokers.
Main outcome measures We estimated time trends in the proportion of smokers reporting purchasing tobacco from (i) cross-border and (ii) illicit sources in the past 6 months, and examined associations with motivation to stop smoking (among current smokers) and past-year quit attempts (among past-year smokers).
Results Between February 2019 and October 2022, there was a non-linear increase in the proportion of smokers reporting purchasing cross-border tobacco (from 5.2% to 16.1%; PR=3.10, 95%CI=2.03-4.73) but no overall change in the proportion reporting purchasing illicit tobacco (from 9.2% to 8.5%; PR=0.92, 95%CI=0.70-1.21). Both cross-border (ORadj=0.65, 95%CI=0.56-0.77) and illicit (ORadj=0.74, 95%CI=0.63-0.86) tobacco purchasing were associated with lower odds of reporting a recent quit attempt. Smokers who purchased cross-border tobacco also reported lower motivation to stop smoking (ORadj=0.84, 95%CI=0.75-0.95).
Conclusions Despite a fall in cross-border tobacco purchasing during the first year of the Covid-19 pandemic, the proportion of smokers in England reporting purchasing cross-border tobacco is now three times higher than it was at the start of 2019. The proportion reporting purchasing illicit tobacco has not changed substantially. Tackling the increasing use of cheap tobacco in England may be an important target for motivating quit attempts.
What is already known on this topic Tobacco tax avoidance and evasion strategies, such as buying tobacco cheaply from cross-border or illicit sources, undermine the effectiveness of tax policy.
What this study adds Since February 2019, the proportion of smokers in England reporting purchasing cross-border tobacco has tripled, while the proportion reporting purchasing illicit tobacco remains similar. Smokers who use cheap tobacco are less likely to try to quit.
How this study might affect research, practice or policy Policy measures that reduce smokers’ access to these cheaper sources of tobacco could help to increase the rate of quit attempts among smokers and accelerate progress toward the government’s smokefree 2030 target.
Competing Interest Statement
JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Clinical Protocols
Funding Statement
Cancer Research UK (PRCRPG-Nov21\100002) funded the Smoking Toolkit Study data collection and SJ's salary.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymized when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
